Identifying Occult Maternal Malignancies From 1.93 Million Pregnant Women Undergoing Noninvasive Prenatal Screening Tests

• DOI: 10.1097/01.ogx.0000657372.14204.f0
• Publication Date: 2020-06-02T18:17:15Z
• Authors: Xing Ji; Jia Li; Yonghua Huang; Pi-Lin Sung; Yuying Yuan; Qiang Liu; Yan Chen; Jia Ju; Yafeng Zhou; Shujia Huang; Fang Chen; Yuan Han; Wen Yuan; Cheng Fan; Qiang Zhao; Haitao Wu; Suihua Feng; Weiqiang Liu; Zhihua Li; Jingsi Chen; Min Chen; Hong Yao; Li Zeng; Tao Ma; Shushu Fan; Jinman Zhang; Ka Yiu Yuen; So Hin Cheng; Irene Wing Shan Chik; Nien-Tzu Liu; Jianyu Zhu; Siyuan Lin; Jeremy Cao; Steve Tong; Zhiyuan Shan; Wenyan Li; Mohammad Reza Hekmat; Masoud Garshasbi; Javier Suela; Yaima Torres; Juan C. Cigudosa; F. J. Pérez Ruiz; Laura Rodríguez; Mónica García; Janez Bernik; Eva Traven; Uršula Reš; Nataša Tul; Ching-Fong Tseng; Depeng Zhao; Luming Sun; Qiong Pan; Li Shen; Mengyao Dai; Yuying Wang; Jian Wang; Huanming Yang; Ye Yin; Tao Duan; Baosheng Zhu; Mahesh Choolani; Xin Jin; Yingwei Chen; Mao Mao
• Keywords: Cell-free fetal DNA; Occult; Prenatal screening

(Abstracted from Genet Med 2019;21:2293–2302) Noninvasive prenatal screening for aneuploidy using cell-free DNA (cfDNA) has been used since 2011 to identify fetal genetic disorders such as trisomies 13, 18, and 21. However, these tests can give false-positive results or fail all together when other conditions, maternal cancer, are present.